Provider Newsflash
August 2026

FDA Recall – Baxter 0.9% Sodium Chloride Injection 500 mL

Purpose of this communication:

We are writing to inform you that Baxter International Inc. is voluntarily recalling two lots of 0.9% Sodium Chloride Injection, USP, 500 mL VIAFLEX Plastic Container due to the potential presence of particulate matter identified as fiberglass in the solution. The affected product is Product Code 2B1323Q, 0.9% Sodium Chloride Injection, USP, 500 mL VIAFLEX Plastic Container, Lot Numbers Y495523 and Y495523A, Expiration Date 31-Oct-2027, NDC Number 0338-0049-03. Intravenous administration of affected product may lead to serious adverse health consequences, including blockage and clotting in blood vessels, pulmonary embolism, permanent organ damage, local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, or death. The product is indicated as a source of water and electrolytes and for use as a priming solution in hemodialysis procedures. The impacted product was distributed from July 31, 2026, through August 3, 2026, to healthcare providers and distributors in select U.S. states, including Indiana. As of August 25, 2026, Baxter had not received reports of adverse events related to this issue.

What do I need to do?

- Please review the FDA recall notice here.
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to guidelines issued by the manufacturer in the FDA notification
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.